Skip to content
CancerIndex

Publication

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Authors not recorded

Int J Cancer2016PMID 26686064stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
26686064
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
RET Overexpression2
VandetanibMalignant Breast NeoplasmPredictiveDSupports Sensitivity Response2accepted
EID740

Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandeta… (full text at CIViC)

PMID 26686064 · Hatem et al., 2016 · Open in CIViC

civic
〃Estrogen Receptor-negative Breast CancerUNRESOLVEDPredictiveDSupports Sensitivity Response3submitted
EID2992

The activity of Vandetanib was tested in vivo in three PDX models of TNBC and one model of HER2+ BC with different expression levels of RET and EGFR. Vandetanib induced tumor regression in PDX models … (full text at CIViC)

PMID 26686064 · Hatem et al., 2016 · Open in CIViC

civic